Insider to sell 1,018,875 AMPX shares in plan filing (NYSE: AMPX stock)
Rhea-AI Filing Summary
A shareholder filed a Form 144 to sell 1,018,875 common shares on the NYSE, showing an aggregate market value of $10,341,581.25. The shares are to be sold through Morgan Stanley Smith Barney LLC, with an approximate sale date of 01/16/2026, and the filing notes that 130,483,838 shares of the issuer’s stock are outstanding.
The securities to be sold were acquired on 01/16/2026 via the exercise of stock options from the issuer, paid in cash. Over the past three months, the same account reported additional common stock sales, including 1,000,000 shares sold on 11/17/2025 for $10,595,300.00 and 506,267 shares sold on 01/12/2026 for $5,111,474.14, some under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
FAQ
What does the AMPX Form 144 filing report?
The Form 144 reports a shareholder’s intent to sell 1,018,875 common shares of AMPX on the NYSE, with an aggregate market value of $10,341,581.25, through Morgan Stanley Smith Barney LLC.
How many AMPX shares are planned to be sold under this Form 144?
The filing states that 1,018,875 common shares are planned to be sold, with an approximate sale date of 01/16/2026.
How were the AMPX shares in this Form 144 acquired?
The shares were acquired on 01/16/2026 through the exercise of stock options from the issuer, and the payment method is listed as cash.
What does the Form 144 say about AMPX shares outstanding?
The Form 144 lists 130,483,838 common shares of the issuer as outstanding at the time of the filing.
What recent AMPX stock sales are disclosed for this shareholder?
Over the past three months, disclosed sales include 1,000,000 common shares sold on 11/17/2025 for $10,595,300.00 and 506,267 shares sold on 01/12/2026 for $5,111,474.14, with some transactions labeled as 10b5-1 sales.
What is the role of Rule 10b5-1 in the AMPX Form 144 filing?
The filing references 10b5-1 sales for the named seller and includes a representation that the person does not know of any material adverse information about the issuer that has not been publicly disclosed.